Targeted inhibition of Snail family zinc finger transcription factors by oligonucleotide-Co(III) Schiff base conjugate.

Department of Chemistry, Northwestern University, Evanston, IL 60208, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 09/2009; 106(33):13667-72. DOI: 10.1073/pnas.0906423106
Source: PubMed

ABSTRACT A transition metal complex targeted for the inhibition of a subset of zinc finger transcription factors has been synthesized and tested in Xenopus laevis. A Co(III) Schiff base complex modified with a 17-bp DNA sequence is designed to selectively inhibit Snail family transcription factors. The oligonucleotide-conjugated Co(III) complex prevents Slug, Snail, and Sip1 from binding their DNA targets whereas other transcription factors are still able to interact with their target DNA. The attachment of the oligonucleotide to the Co(III) complex increases specificity 150-fold over the unconjugated complex. Studies demonstrate that neither the oligo, or the Co(III) Schiff base complex alone, are sufficient for inactivation of Slug at concentrations that the conjugated complex mediates inhibition. Slug, Snail, and Sip1 have been implicated in the regulation of epithelial-to-mesenchymal transition in development and cancer. A complex targeted to inactivate their transcriptional activity could prove valuable as an experimental tool and a cancer therapeutic.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Chemical manipulation of natural, unengineered proteins is a daunting challenge which tests the limits of reaction design. By combining transition-metal or other catalysts with molecular recognition ideas, it is possible to achieve site-selective protein reactivity without the need for engineered recognition sequences or reactive sites. Some recent examples in this area have used ruthenium photocatalysis, pyridine organocatalysis, and rhodium(II) metallocarbene catalysis, indicating that the fundamental ideas provide opportunities for using diverse reactivity on complex protein substrates and in complex cell-like environments. Copyright © 2014 Elsevier Ltd. All rights reserved.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Matrix metalloproteinases (MMPs) are a family of zinc binding endopeptidases that play crucial roles in various physiological processes and diseases such as embryogenic growth, angiogenesis, arthritis, skin ulceration, liver fibrosis and tumor metastasis. 1,2 Because of their implications in a wide range of diseases, MMPs are considered as intriguing drug targets. The majority of MMP inhibitors are organic small molecules containing a hydroxamate functionality for the zinc binding group. This hydroxamate group binds to a zinc(II) center in a bidentate fashion and creates a distorted trigonal bipyramidal geometry. 3 Although the hydroxamate group is the most effective zinc binding moiety reported, it has shown two major limitations in clinical trials: low bio-availability and lack of specificity. 4,5 Because the hydroxa-mate group is prone to rapid metabolism and has a high binding affinity towards various transition metals, many efforts have been made to develop novel zinc binding groups, including reverse hydroxamate, phosphate, and pyridinone. However, the in vitro activity of these newly developed inhibitors are not as high as the hydroxamate derivatives. 6,7 It was previously reported that cobalt(III) acacen complexes could interact with histidine residues of proteins and model peptides. 8-11 The cobalt(III) complexes bind histidine residues in active sites and on enzyme surfaces in a random fashion. Spectroscopic and chromatographic data suggested that the complexes bind to a histidine residue by axial ligand sub-stitution. When an appropriate targeting group is attached, the cobalt(III) complexes can selectively inhibit the histidine-containing enzymes such as thermolysin, 8 human α-throm-bin, 9 and carbonic anhydrase. 9 Since histidine is the most commonly found residue in the active sites of zinc enzymes and zinc-binding proteins, 12 it has been demonstrated that the cobalt(III) complexes can interact with zinc finger pro-teins, such as HIV-1 nucleocapsid protein NCp7 and human zinc finger transcription factor Sp1. 11 It was also reported that a Co(III) complex with a oligonucleotide targeting Snail family zinc finger transcription factor resulted in a selective inactivation of a transcriptional activity implicated in em-bryonic development and breast cancer. 13 In this work, a series of the cobalt(III) complexes are pre-pared as novel MMP inhibitors. Since cobalt(III) complexes have high affinity towards histidine residues and zinc bind-ing proteins, they can be engineered to disrupt the zinc bind-ing active site of MMP. Furthermore, the cobalt(III) complexes may be able to provide better solubility and higher binding affinity than the known organic inhibitors. To test this hypo-thesis, a series of cobalt(III) complexes were designed and synthesized. For active site directing groups, biphenyl sulfo-nate and biphenyl amide group were chosen based on the structures of well known MMP inhibitors. 14 In vitro activity of these complexes was evaluated for MMP-9 (gelatinase B), because MMP-9 is one of the most highly expressed MMPs in tumors and has been implicated in tumor aggressiveness. 5 The syntheses of cobalt(III) complexes are shown in Schemes 1-2. The synthesis of 1 and 2 begins with the methylation of commercially available Cbz-Lys(Boc)-OH as Scheme 1. Synthesis of cobalt(III) complexes 1 and 2.
    Bulletin- Korean Chemical Society 08/2012; 33(8). DOI:10.5012/bkcs.2012.33.8.2762 · 0.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A small molecule containing a rhodium(II) tetracarboxylate fragment is shown to be a potent inhibitor of the prolyl isomerase FKBP12. The use of small molecules conjugates of rhodium(II) is presented as a general strategy for developing new protein inhibitors based on distinct structural and sequence features of the enzyme active site. Copyright © 2014 Elsevier Ltd. All rights reserved.
    Bioorganic & Medicinal Chemistry Letters 11/2014; 24(22). DOI:10.1016/j.bmcl.2014.09.068 · 2.33 Impact Factor


Available from